Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence
- 8 April 2011
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 52 (sup2) , 75-78
Abstract
The purine analogs pentostatin and cladribine are effective treatments for hairy cell leukemia (HCL). However, alternative treatments are needed for patients with recurrent disease. We reviewed retrospectively data from 18 patients who were retreated with either pentostatin (n = 12) or cladribine (n = 6) in combination with rituximab, after 1–6 (median 2) previous treatments with either purine analog as a single agent. All 18 patients responded to therapy, with a complete response (CR) rate of 89%. This compared favorably with CR rates of 68% after second-line therapy and 47% after third-line therapy in 88 patients retreated one or more times with a purine analog alone. Toxicity with the combination treatment was minimal. At a median follow-up of 36 months (range 5–83 months) all 16 complete responders remained in CR, while one partial responder developed recurrent disease at 10 months. The estimated recurrence rate at 3 years was 7%. This compares with 21% after second-line therapy and 42% after third-line therapy in the 88 patients retreated with a purine analog alone. Furthermore, it was a marked improvement on the 55% recurrence at 3 years previously seen in these same 18 patients after their own first-line treatment with single-agent pentostatin or cladribine (p = 0.006). The combination of a purine analog with rituximab was safe and effective for patients with recurrent HCL. The results suggest an added benefit compared with single-agent purine analog therapy.Keywords
This publication has 12 references indexed in Scilit:
- Hairy cell leukemiaCancer, 2010
- Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosisBritish Journal of Haematology, 2009
- Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow‐upBritish Journal of Haematology, 2008
- The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemiaCancer, 2007
- Eradication of minimal residual disease in hairy cell leukemiaBlood, 2006
- Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experienceBlood, 2005
- Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011Blood, 2005
- An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosineLeukemia, 2004
- Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With CladribineJournal of Clinical Oncology, 2003
- Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patientsLeukemia, 2003